Cargando...
The impact of design and performance in PSA screening: differences between ERSPC centers
The European Randomized study of Screening for Prostate Cancer (ERSPC) has shown a 20% relative reduction in prostate cancer mortality after 16 years (rate ratio RR 0.80), but centers varied by attendance, screen interval, biopsy compliance, contamination in the control arm and treatments. We used a...
Guardado en:
| Publicado en: | Eur Urol |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6800079/ https://ncbi.nlm.nih.gov/pubmed/31031050 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2019.04.007 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|